ProQR Therapeutics N.V. (PRQR)
NASDAQ: PRQR · Real-Time Price · USD
1.930
+0.010 (0.52%)
At close: Aug 17, 2026, 4:00 PM EDT
1.920
-0.010 (-0.52%)
After-hours: Aug 17, 2026, 4:34 PM EDT

ProQR Therapeutics Financials Overview

Millions EUR. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
18.4216.3519.556.594.362.38
Revenue Growth
7.49%-16.36%196.41%51.27%83.30%131.10%
Gross Profit
18.4216.3519.556.594.362.38
Operating Income
-42.85-43.45-30.47-34.79-65.16-57.21
Net Income
-42.04-42.18-27.76-28.12-64.42-60.74
Earnings Per Share
-0.39-0.40-0.32-0.35-0.90-0.95
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
117.1392.41149.41118.9394.78187.52
Total Debt
15.3115.9617.2219.7321.9760.37
Net Cash (Debt)
101.8176.45132.1999.1972.8127.15
Net Cash Growth
-1.06%-42.17%33.27%36.24%-42.74%205.94%
Net Cash Per Share
0.960.731.541.221.021.98

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-49.01-52.79-36.3921.55-68.51-26.01
Capital Expenditures
-1.15-1.02-1.42-1.37-0.71-0.48
Free Cash Flow
-50.16-53.81-37.8120.18-69.22-26.5
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
100.00%100.00%100.00%100.00%100.00%100.00%
Operating Margin
-232.60%-265.77%-155.91%-527.60%-1494.82%-2405.80%
Pretax Margin
-228.04%-257.94%-143.05%-421.79%-1470.70%-2551.81%
Profit Margin
-228.18%-258.05%-142.05%-426.43%-1477.95%-2554.25%
FCF Margin
-272.25%-329.18%-193.46%305.99%-1587.89%-1114.21%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
P/FCF Ratio
---7.21--
PS Ratio
12.9411.0913.5222.0556.74210.75